Private Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Private Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,962	Closed	-$456K	–	105
2020 Q4	$456K	Buy	+1,962	New	+$455K	0.09%	66
2020 Q1	–	Sell	-6,940	Closed	-$2M	–	79
2019 Q4	$2M	Sell	6,940 -877	-11%	-$190K	0.49%	40
2019 Q3	$1.13M	Sell	7,817 -27,310	-78%	-$3.7M	0.31%	47
2019 Q2	$3.16M	Buy	35,127 +5,467	+18%	+$439K	0.89%	35
2019 Q1	$2.6M	Hold	29,660	–	–	0.79%	35
2018 Q4	$4.17M	Sell	29,660 -1,933	-6%	-$326K	1.49%	25
2018 Q3	$8.07M	Buy	31,593 +3,800	+14%	+$1.05M	2.23%	16
2018 Q2	$7.08M	Buy	+27,793	New	+$6.87M	2.22%	15

Other funds holding KPTI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Private Capital Advisors's KPTI Position: Q1 2021 in Review

Private Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2021, closing a stake of 1,962 shares — an estimated $456K sold.

Private Capital Advisors first reported a position in KPTI in Q2 2018 and held it in 8 quarters. The position peaked at $8.07M in Q3 2018. 171 funds tracked by Wall St. Rank hold KPTI as of Q1 2021.

Private Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2021 after selling out during the quarter.
Private Capital Advisors sold 1,962 Karyopharm Therapeutics shares in Q1 2021, an estimated $456K.
Private Capital Advisors first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 8 quarters.
Private Capital Advisors's Karyopharm Therapeutics position peaked at $8.07M in Q3 2018.
171 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2021.

Based on Private Capital Advisors's 13F filing for Q1 2021, filed 3 May 2021.